Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.60
Bid: 111.00
Ask: 111.40
Change: 0.00 (0.00%)
Spread: 0.40 (0.36%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 110.60
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS SUMMARY: IAG Chair And Director Spend EUR1.2 Million

Thu, 05th Mar 2020 15:41

(Alliance News) - The follow is a round-up of share dealings by UK company directors and managers announced on Thursday and not separately reported by Alliance News:

----------

International Consolidated Airlines Group SA - Non-Executive Chair Antonio Vazquez Romero buys 84,000 shares at EUR5.34, worth EUR448,896, and Non-Executive Director Francisco Javier Ferran Larraz buys 144,000 at EUR5.22 average price, worth GBP751,968. The EUR1.2 million in purchases were made on Tuesday.

----------

Anexo Group PLC - Executives sell GBP4.4 million in shares on Tuesday, all at 150 pence per shares, "in response to institutional demand". Executive Chair Alan Sellers and Bond Turner Managing Director Samantha Moss each sell 1.3 million shares, while Sales Director Tina Slater sells 290,000. Sellers now holds 36.4 million shares, a 33% holding, Moss 37.4 million for 34%, and Slater 7.4 million for 6.7%.

----------

Syncona Ltd - Non-Executive Director Thomas Henderson sells 1.0 million shares, via Farla Ltd, at GBP2.47, worth GBP2.5 million, on Tuesday. Syncona has a market capitalisation of GBP1.62 billion.

----------

London Stock Exchange Group PLC - Waqas Samad, director of information services & chief executive officer of FTSE Russell, sells 20,890 shares at GBP79.00, worth GBP1.7 million. Non-Executive Director Val Rahmani buys 1,129 shares at GBP79.27, worth GBP89,499. Both on Wednesday.

----------

Elad Ben Izhak - Co-Founder Elad Ben Izhak buys 53,000 shares at GBP9.50, worth GBP503,500, on Tuesday.

----------

Elementis PLC - Chief Financial Officer Ralph Hewins buys 15,034 shares at GBP1.00, worth GBP15,000, on Wednesday.

----------

Tyman PLC - Non-Executive Director Paul Withers buys 25,000 shares at GBP2.54, worth GBP63,488, on Thursday. Withers joined the Tyman board at the start of February.

----------

Signature Aviation PLC - Chief Executive Mark Johnstone buys 13,980 shares at 284.61p, worth GBP39,788, on Tuesday. Now holds 297,016 shares.

----------

Hiscox Ltd - Independent Non-Executive Director Colin Keogh buys 2,100 shares at GBP12.11, worth GBP25,441, on Tuesday. CFO Hamayou Akbar Hussain buys 1,300 shares at GBP12.22, worth GBP15,884, on Wednesday.

----------

Kingswood Holdings Ltd - Non-Executive Director David Hudd buys 200,000 shares at 24.5p, worth GBP49,000, on Wednesday. Purchase is his only holding.

----------

Hammerson PLC - Non-Executive Director Adam Metz buys 20,000 shares at GBP1.99, worth GBP39,800, on Wednesday.

----------

Eden Research PLC - Non-Executive Chair Lykele van der Broek buys 571,000 shares at 6.65p average price, worth GBP37,972, on Wednesday. Now holds 929,500 shares.

----------

Wizz Air Holdings PLC - Claude Bertrac, partner of Chief Corporate Officer Marion Geoffroy, buys 400 shares at GBP33.50, worth GBP13,400, on Monday.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
11 May 2022 09:30

Syncona investee Freeline narrows quarterly loss as costs fall

(Alliance News) - Healthcare company investor Syncona Ltd on Wednesday noted that its portfolio company Freeline Therapeutics PLC trimmed its loss for the first quarter of 2022.

Read more
10 May 2022 14:26

IN BRIEF: Syncona investee Achilles widens quarterly loss on costs

Syncona Ltd - investor in healthcare companies - Notes investee company Achilles Therapeutics PLC posts widened loss amid rising research & development costs. Pretax loss in the quarter ended March 31 widens to USD17.3 million from USD13.8 million a year ago. Research & development costs surge to USD13.0 million from USD8.9 million, mainly due to increased activity in ongoing clinical trials. Cash and equivalents on March 31 fall to USD236.9 million from USD266.3 million as of December 31. "The company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second half of 2024," Achilles says.

Read more
5 May 2022 12:59

IN BRIEF: Syncona's investee Autolus widens quarterly loss as costs up

Syncona Ltd - London-based healthcare & investment company - Reports quarterly loss for its portfolio company Autolus Therapeutics PLC as research costs rise. Net loss widens to USD42.7 million from USD39.0 million a year ago. Research & development expenses rise to USD34.0 million from USD30.7 million, Syncona explains.

Read more
28 Apr 2022 12:52

IN BRIEF: Syncona invests GBP15 million more in OMass Therapeutics

Syncona Ltd - London-based investment company - Invests more into OMass Therapeutics, an Oxford University biotechnology spin-out. After the new GBP15 million investment, Syncona now holds a 31% stake worth GBP44 million in the developer of small molecule drugs. The GBP15 million is part of an oversubscribed GBP75.5 million second round of funding for OMass, which now has raised GBP119 million in total.

Read more
28 Apr 2022 08:59

Syncona takes part in oversubscribed funding round for OMass

(Sharecast News) - Syncona committed further funding for rare-disease specialist OMass Therapeutics alongside a syndicate of investors which included a unit of French drug giant Sanofi.

Read more
11 Apr 2022 09:25

Syncona's investee Anaveon receives good trial data

(Alliance News) - Syncona Ltd on Monday noted that its portfolio company Anaveon AG received "encouraging" first clinical data from its ongoing phase I/II study for ANV419.

Read more
11 Apr 2022 07:49

Syncona's Anaveon to present first clinical data from ANV419 study

(Sharecast News) - Healthcare company Syncona said on Monday that its portfolio company, Anaveon AG, a clinical-stage immuno-oncology business, had announced that the first clinical data from the ongoing Phase I/II study of its lead programme, ANV419, would be presented in a poster at the American Association for Cancer Research's annual meeting in New Orleans.

Read more
1 Apr 2022 07:32

Syncona notes portfolio company Freeline annual loss widens in 2021

(Alliance News) - Syncona Ltd said on Friday that portfolio company Freeline Therapeutics Holdings PLC suffered a widened loss last year.

Read more
11 Mar 2022 08:44

Syncona to invest further USD20 million in Freeline Therapeutics

(Alliance News) - Syncona Ltd said on Friday that it agreed to invest USD20.0 million in Freeline Therapeutics Holdings PLC, as part of the investee's USD26.1 million American depositary shares offering.

Read more
18 Feb 2022 10:03

Syncona completes USD1.5 billion sale of Gyroscope to Novartis

(Alliance News) - Syncona Ltd on Friday said it has completed the sale of Gyroscope Therapeutics Holding PLC to Novartis AG.

Read more
10 Feb 2022 07:47

Syncona's Q3 a 'period of significant activity'

(Sharecast News) - Life sciences firm Syncona said on Thursday that the third quarter had been a "period of significant activity", with $674.0m raised by its portfolio and its third successful exit to date.

Read more
8 Feb 2022 20:38

IN BRIEF: Syncona's Freeline says FLT190 drug "well tolerated"

IN BRIEF: Syncona's Freeline says FLT190 drug "well tolerated"

Read more
22 Dec 2021 17:03

LONDON MARKET CLOSE: Omicron hope lifts FTSE despite UK virus surge

LONDON MARKET CLOSE: Omicron hope lifts FTSE despite UK virus surge

Read more
22 Dec 2021 12:21

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

Read more
22 Dec 2021 10:51

TOP NEWS SUMMARY: Novartis agrees to buy UK's Gyroscope Therapeutics

TOP NEWS SUMMARY: Novartis agrees to buy UK's Gyroscope Therapeutics

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.